Position-93 Reactive Cysteine Antibodies for Homogeneous ADCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody drug conjugates (ADCs) face challenges with heterogeneous drug-to-antibody ratios (DARs) due to random conjugation to lysine or hinge cysteine residues, leading to complex mixtures with varying pharmacokinetics and pharmacodynamics, and there is a need for more efficient generation of homogeneous ADCs with single and multiple payloads.
Innovation Solution
The development of antibody compounds with engineered cysteine residues at position 93 of the heavy chain variable region, allowing for site-specific conjugation using dibromomaleimide derivatives, resulting in stable and homogeneous ADCs with defined drug-to-antibody ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If random conjugation to lysine or hinge cysteine residues is used, then ease of manufacture is improved, but manufacturing precision deteriorates due to heterogeneous drug-to-antibody ratios
Solution Approach 1:
The patent applies local quality by creating a specific reactive cysteine residue at a defined location (position 93 of the heavy chain variable region) within the antibody molecule. This engineered cysteine provides a unique, localized conjugation site that enables site-specific drug attachment, transforming the random conjugation process into a controlled, precise reaction at a predetermined location.
Solution Approach 2:
The patent implements preliminary action by pre-engineering the cysteine residue at position 93 of the heavy chain variable region before conjugation. This preliminary modification of the antibody structure creates a ready-made reactive site that directs the subsequent drug conjugation to a specific location, ensuring homogeneous drug-to-antibody ratios without requiring complex purification processes.
2Manufacturing precision
If site-specific conjugation using engineered cysteine residues is used, then manufacturing precision is improved, but device complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying a specific parameter of the antibody molecule - the amino acid sequence at position 93 of the heavy chain variable region. By changing this single parameter from the wild-type sequence to an engineered cysteine residue, the patent achieves site-specific conjugation capability without fundamentally altering the overall antibody structure or conjugation chemistry, thus minimizing complexity.
3Ease of operation
If random conjugation is used, then ease of operation is improved, but stability deteriorates due to heterogeneous pharmacokinetics and pharmacodynamics
Solution Approach 1:
The patent applies local quality by creating a specific reactive cysteine residue at a defined location (position 93 of the heavy chain variable region) within the antibody molecule. This engineered cysteine provides a unique, localized conjugation site that enables site-specific drug attachment, transforming the random conjugation process into a controlled, precise reaction at a predetermined location.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered cysteine-based conjugation strategy enables precise, fast, and efficient assembly of ADCs with single or dual payloads, maintaining stability and potency, similar to h38C2-based ADCs, and allows for targeted delivery to tumor cells.
Implementation Method 1
a linker, and a potent cytotoxic payload... all use either natural lysine (3) or cysteine (8) residues for linker-drug attachment due to their surface accessibility and the nucleophilicity of their α-amino and thiol group, respectively
Data Source
AI summary
The present invention provides antibody compounds that contain a substitution of cysteine for the reactive lysine residue (lysine 93 by Kabat numbering) in the hydrophobic cleft (38C2_Cys). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered cysteine residue in the 38C2_Cys variant antibody. Further provided in the invention are therapeutic applications of the compounds.